Science Pool

Evotec

Recent Posts

3D Cell Models DDup #12

Posted by Evotec on Mar 10, 2022 11:38:33 AM

The 12th edition of our Drug Discovery Update (DDup) provides insights into exciting new developments in 3D cell models including microtissues, organoids and organ-on-a-chip technology.

In this edition, it covers:

  • an introduction to 3D cellular models
    • the need for better models to improve translation from in vitro to in vivo
    • the relevance of 3D cellular models to kidney disease modelling and drug induced toxicity prediction
  • an overview of Evotec's 3D in vitro platforms
    • glomerulus-on-a-chip to study kidney disease
    • kidney organoids to study polycystic kidney disease
    • organ microtissues to predict drug-induced toxicity
  • interviews with experts Dr Christodoulos Xinaris, Dr Reiner Class, Dr Magali Ferro and Dr Stephanie Ryder

LEARN MORE

Tags: Kidney diseases, Articles & Whitepapers, Toxicology & Safety, Metabolic Disease & Complications

Development of a Ligand for In Vivo Imaging of Mutant Huntingtin in Huntington’s Disease

Posted by Evotec on Mar 10, 2022 10:24:55 AM

Huntington´s Disease (HD) is a hereditary neurodegenerative disorder that is caused by a mutation in the huntingtin gene (mHTT) leading to deposition of pathologic protein aggregates in the brain.

This paper focuses on:

  • Visualization of mHTT aggregate expression by positron emission tomography (PET) in rodent HD model
  • Utility of the previously described novel PET imaging ligand CHDI-180 for detection of mHTT in rodent and post-mortem human HD brain
  • Ability of CHDI-180 to serve as functional response indicator for mHTT lowering therapies

GET THE PAPER

Tags: Medicinal Chemistry, Articles & Whitepapers, Proteomics, Metabolomics & Biomarkers

American Biomanufacturing Summit

Posted by Evotec on Mar 10, 2022 9:23:23 AM

Date: 13 - 14 April 2022

Location: Hyatt Regency San Francisco Airport, San Francisco, CA, United States

Who's Attending? 

  • John Gunther, Senior Director Business Development at Just - Evotec Biologics

 

Presentation
Advanced Continuous Manufacturing Solutions to Accelerate Time to Clinic and Secure Cost-Effective Commercial Supply

  • The talk will be given by Magnus Schroeder, VP Process and Product Design at Just - Evotec Biologics


If you wish to meet with us in San Francisco, get in touch via the form below, we will be happy to arrange a meeting. We hope to see you there!

Tags: Events, Evotec, Just Evotec Biologics

BSL3 High Throughput Screening Capabilities Fact Sheet

Posted by Evotec on Mar 8, 2022 5:05:24 PM

With more then 15 years of screening experience in anti-infectives, including antibacterials and antivirals, Evotec's medium throughput and high throughput screening expertise extends to BSL2+ and BSL3 containment level. 

DOWNLOAD NOW

Tags: Fact Sheets, Hit & Target ID/Validation, Anti-Infectives

Anti-Infective Virology Fact Sheet

Posted by Evotec on Mar 8, 2022 4:53:46 PM

Download this fact sheet to learn more about Evotec's anti-infectives virology platform including: 

  • Full integration
  • Project based flexibility tailoring
  • Development of novel tools


DOWNLOAD NOW

Tags: Fact Sheets, In vitro Biology, Anti-Infectives

Learn about our Global Anti-Infective Platform

Posted by Evotec on Mar 2, 2022 3:02:49 PM

Tags: SP Standalone

Read our Whitepaper: The Hollow Fibre Infection Model

Posted by Evotec on Mar 2, 2022 3:01:41 PM

Tags: SP Standalone

Read our Fact Sheet on the Hollow Fibre Infection Model

Posted by Evotec on Mar 2, 2022 3:01:12 PM

Tags: SP Standalone

Dive into our New Science Pool

Posted by Evotec on Mar 2, 2022 3:00:24 PM

Tags: SP Standalone

E.SOLVE: Solving Bioavailability Challenges Fact Sheet

Posted by Evotec on Mar 2, 2022 1:37:10 PM

RZ_E_SOLVE-Logo+Tagline_211004_Screen_Blue-png

E.SOLVE is Evotec's solution to accelerate your journey to the clinic supporting your formulation strategy as early as possible from discovery to market approval.

Download this fact sheet to learn more about how E.SOLVE's full range of approaches improve solubilization and bioavailability to ensure that your API can progress through the drug discovery development pipeline faster.

DOWNLOAD

Tags: IND Enabling, Fact Sheets, Formulation & CMC, Toxicology & Safety